Filing Flows › Health Care › Ceribell (CBLL)
Ceribell (CBLL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Ceribell (CBLL) Q3 2026 earnings results →
Q3 2026 Revenue up 30% year over year to $29.3M · 73¢ of every $1 of revenue lost · operating margin -70.0%
Ceribell made $29.3M in Q3 2026 (+30% Y/Y): Product $22.2M, Subscription $7.1M. Operating margin -70.0%, net loss $21.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $29.3M in Q3 2026, up 30% year over year and up 4% from the previous quarter. Product was the largest line at 76% of revenue. Product added $5.2M year over year (up 31%), 77% of the total change.
Gross margin was 89.8%, up 1.5 points from Q3 2025. Operating costs exceeded revenue by $20.5M, an operating margin of -70.0%. Operating expenses grew 36% against revenue growth of 30%. The fastest-growing cost line was Research & development (+49%). The quarter ended with a net loss of $21.4M, wider than the previous quarter's $19.3M loss.
Operating cash flow was −$13.1M. Non-cash charges added back $249K of depreciation and amortization and $7.1M of share-based compensation. Working capital and other items added $926K. Capital expenditures of $100K exceeded it, leaving free cash flow of −$13.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $29.3M | +30% | -70.0% | −$21.4M | −$13.1M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $28.1M | +32% | -71.1% | −$19.3M | −$12.9M |
| Q1 2026 | 10-Q | May 11, 2026 | $26.5M | +29% | -78.3% | −$19.7M | −$19.3M |
| Q4 2025 | 10-K | Feb 24, 2026 | $24.8M | +34% | -58.9% | −$13.5M | −$10.8M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $22.6M | +31% | -64.8% | −$13.5M | −$11.1M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $21.2M | +38% | -70.5% | −$13.6M | −$7.5M |
| Q1 2025 | 10-Q | May 8, 2025 | $20.5M | +42% | -69.3% | −$12.8M | −$11.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Ceribell
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn .
In its own words, from its 8-K, filed Aug 10, 2026.
Ceribell against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +30% against the peers' median +14%. Operating margin: -70.0% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| BLFS Biolife Solutions | Q2 2026 | $28.5M | +22% | 6.0% |
Source: Ceribell 10-Q on SEC EDGAR · CIK 1861107 · Electromedical & Electrotherapeutic Apparatus
13F: who owns CBLL and who is buying
More on CBLL
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results